Salud
Cigna says it is not seeking a deal with rival Humana
Cigna Group said it is not seeking a merger with rival health insurer Humana. Days after Donald Trump’s re-election as US president, investors harboured hopes
AstraZeneca raises its 2024 outlook
Drugmaker AstraZeneca raised its annual sales and profit forecast for the second time this year, helped by strong demand for its cancer and rare disease
Bayer shares fall to a 20-year low
Bayer said weak agricultural markets mean its profits are likely to fall further next year, triggering a sharp drop in the German company’s shares and
FDA approves Johnson & Johnson device for heart disease
The US FDA has approved J&J’s device for a type of condition that causes abnormal heart rhythms, the company said. The device, Varipulse, is a
Moderna reports unexpected profit due to higher sales of COVID vaccine
Moderna on Thursday reported an unexpected third-quarter profit, driven by cost cuts and better-than-expected sales of its COVID-19 vaccine, even though revenue from its new
Australia approves $5.8bn Chemist Warehouse-Sigma Healthcare deal
Australia’s competition regulator on Thursday approved the reverse takeover of Sigma Healthcare by private pharmacy chain Chemist Warehouse, paving the way for the A$8.8 billion
Novo Nordisk is aware of 10 deaths from counterfeit weight loss products
Novo Nordisk on Wednesday the company said it was aware of 10 deaths and 100 hospitalisations as a result of people taking combination copies of
Siemens Healthineers hit full-year revenue and profit forecasts, shares up 8%
Siemens Healthineers on Wednesday the company met forecasts for full-year revenue and profit growth as strength in its imaging segment and U.S. cancer treatment unit
Novo Nordisk lifts restrictions on Wegovy prescriptions in the US, CEO says
Novo Nordisk is lifting prescription restrictions on its weight-loss drug Wegovy in the United States and increasing shipments to that market, its chief executive said
Novartis CEO ‘very confident’ in his sales plans and not afraid of patent collapse
Novartis CEO Vas Narasimhan said in an interview on Saturday that he expects to increase its annual sales by at least 5 per cent a